Iron and aluminum in Alzheimer’s disease

Francesco Di Lorenzo, Berardino Di Lorenzo

“Ambulatorio Privato di Scienze Mediche”, Valenzano, Bari, Italy

Correspondence to: Francesco Di Lorenzo, MD.
Via Pigna n.4, 70010 Valenzano, Bari, Italy.
TEL: +39-3296163725; E-MAIL: f.dilorenzo@email.it

Submitted: 2013-04-12 Accepted: 2013-10-27 Published online: 2013-11-25

Key words: metals; neurodegenerative disorders; chelation therapy

Abstract

In this case presentation, a woman with high serum levels of aluminum was treated with chelation therapy with deferoxamine and ascorbic acid. This patient was initially bedridden and the clinical situation was complicated by epileptic seizures. After the chelation therapy, the clinical condition was ameliorated and the therapy continued without the correlation to aluminum serum levels. The role of metals in neurodegenerative disorders and the correlation between iron metabolism and amyloid beta peptide are described. This case suggests chelation therapy could represent a promising therapeutic option for this dramatic disease.

INTRODUCTION

The following is the case of a patient with Alzheimer’s disease with behavioral and psychological signs and symptoms of dementia. The case was complicated by epileptic seizures and she was also bedridden. The following are the essential elements of chelation therapy and the radiological and serological tests performed before and during the treatment. Additionally, we provide an extremely synthesized description of the scientific basis for the role of metals in neurodegenerative disorders.

CLINICAL CASE

In March 2008 L.A. was a 71-year-old female, weighing 65 kg. Her father had died from gut cancer and the mother probably suffered from Alzheimer’s disease. Beta-thalassemic herself, she had no other disease. The first symptoms appeared in May 2001. Diagnosis and therapy, which was formulated by the “Unità di Valutazione Alzheimer” (Diagnostic and therapeutic centre for dementias) – Department of Neurology – “Di Venere hospital” – in Bari – Italy reported the following: “Possible Dementia of Alzheimer”. Consequently the neuropsychological evaluation of May 2001 evidenced an MMSE value <20 and activity of daily living and the instrumental activity of daily living were 3 and 2. The consecutive neuroTc reported: “No evidence of densitometric altera-
tion of brain parenchyma. Atrophy of frontal lobes. Ventricular system in axis, no dilatations” (Figure 1). The electroencephalograms of July 2001 reported “Pc/s rytm reactive, badly modulates; diffuse slowing down especially in the temporal lobes”. No particular alterations in serological tests were found. The therapy was: donepezil 5 mg cps once a day.

In January 2002 the patient was found to be in stable condition but she developed behavioral symptoms with depression and irritability. Consequently, the therapy consisted of donepezil 10 mg cps once a day and one 50 mg tablet sertraline once a day.

In July 2002 the patient was diagnosed with sleep disorders. One 10 mg tablet zolpidem once a day was added.

In January 2003 she was found with agitation, irritability, delusions and hallucinations. Consequently risperidone 0.5 mg was added to the therapy; in January 2004 the dosage was elevated to 1 mg; then, after the development of parkinsonism, this drug was substituted by quetiapine 25 mg tablet administered twice daily from February 2008. In May of the same year the patient was bedridden and the situation was complicated by partial epileptic seizures.

In May 2008, due to the seriousness of the situation and the decline of general conditions, the patient was laid off by the neurologist that followed her with ascorbic acid 150 mg im once a day, three times a week.

So, we decided to examine the patient for heavy metal serological levels. In June 2008, we found normal values for zinc, copper, iron and lead but high levels of aluminum (38 mcg/l; n.v. <10 mcg/l). After the comparison from “Centro antiveleni” (Venoms centre) of Milan, we applied the chelation therapy: deferoxamine 500 mg im twice a day with ascorbic acid 150 mg im once a day for six days per month.

In August 2008 her aluminum serum level was 24 mcg/l. The general condition was ameliorated. Epileptic seizures were not occurring.

In September 2008 and October 2008 the values were 12 and 5 mcg/l respectively. There was an enormous clinical improvement: the patient resumed to walk, and there were no epileptic seizures. So, we decided to reduce Phenobarbital for its cognitive effects, and we substituted levetiracetam 1500 mg oral solution twice a day. In November 2008, we abrogated carbamazepine, and in December quetiapine.

Due to this clear improvement, we decided, on the basis of literature’s data, to continue with chelation therapy, specifically, deferoxamine 500 mg im twice a day with ascorbic acid 150 mg im once a day, three times a week.

After six months the patient was found in good condition: no epileptic seizures were noted, irritability and agitation were abolished and she walked unaided. So we reduced levetiracetam to 1000 mg twice daily. The sleep disorders were abolished (she slept for 8 hours a night) and she repeated, if asked, some words, although she wasn’t able to completely resume her speaking. She was stable for five years before she died in March 2013.

RESULTS

Therapy and clinical course

The patient, due to the seriousness of her condition, was treated with chelation therapy. First, for three months she received deferoxamine and ascorbic acid twice a day, every day for six days per month. Then, after positive clinical results, she received therapy twice a day for three times a week in which ascorbic acid was administered once a day. This therapy had the ability to abolish epileptic seizures and to reduce antiepileptic drugs (in particular Phenobarbital, which has a cognitive effect, was eliminated), helping to regain her ability to walk unaided and to prolong survival. No side effects were found and serological values of iron, aluminum, ferritin were found in the range of normality (haemocromocitometric too, considering she was a betathalassemic patient) (Table1).

Deferoxamine (DFO) is a chelation agent against iron and aluminum (Brown et al. 1982; Nebeker et al. 1984). This drug was the first aluminum chelator to be introduced in clinical practice and it was administrated with good efficacy either intramuscularly or intraperitoneally (Ciancioni et al. 1984; Molitoris et al. 1987).

Savory et al. (1998) have demonstrated that DFO can reverse the tau aggregates following two days of treatment in aluminum-induced neurofibrillary degenerations in rabbits.

---

Tab. 1. Correlation between serum levels of aluminum, ferritin and haemoglobin during the therapy. In this period no side effects were found and the values of ferritin and haemoglobin were normal in a patient with beta-thalassemia.

<table>
<thead>
<tr>
<th>Date</th>
<th>Al (mcg/L)</th>
<th>Ferritin (mg/dl)</th>
<th>Hb (g/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2008</td>
<td>38</td>
<td>80</td>
<td>10.2</td>
</tr>
<tr>
<td>July 2008</td>
<td>38</td>
<td>75</td>
<td>10.1</td>
</tr>
<tr>
<td>August 2008</td>
<td>24</td>
<td>45</td>
<td>10.2</td>
</tr>
<tr>
<td>September 2008</td>
<td>12</td>
<td>50</td>
<td>10.3</td>
</tr>
<tr>
<td>October 2008</td>
<td>5</td>
<td>55</td>
<td>10.4</td>
</tr>
<tr>
<td>April 2009</td>
<td>6</td>
<td>57</td>
<td>10.2</td>
</tr>
<tr>
<td>September 2009</td>
<td>5.2</td>
<td>57</td>
<td>10.5</td>
</tr>
<tr>
<td>July 2010</td>
<td>5</td>
<td>68</td>
<td>10.1</td>
</tr>
<tr>
<td>January 2011</td>
<td>5</td>
<td>75</td>
<td>10.6</td>
</tr>
<tr>
<td>September 2011</td>
<td>4.5</td>
<td>74</td>
<td>10.4</td>
</tr>
<tr>
<td>May 2012</td>
<td>5.2</td>
<td>77</td>
<td>10.3</td>
</tr>
<tr>
<td>October 2012</td>
<td>4.8</td>
<td>79</td>
<td>10.5</td>
</tr>
</tbody>
</table>
The effectiveness of intramuscular DFO in AD patients was supposed by other authors (Crapper et al. 1991). The associations with ascorbic acid is intended to guarantee the reduction of Fe$^{3+}$ to Fe$^{2+}$ and Al$^{3+}$ to Al$^{2+}$ and to improve the binding of these metal ions to DFO (Herbert 1999).

**DISCUSSION**

The case described proposes again the role of metals in the pathogenesis of AD. This remark is deeply embedded in the scientific background that considers AD as a multifactorial disease. Iron is strongly involved in amyloidogenesis. Hua et al. (2008). have demonstrated that this process is regulated by furin. In particular toxic insoluble aggregates of amyloid-beta-peptide (AB) are present in the brains of AD patients in extracellular senile plaques and in neurofibrillary tangles (NFT) created by the hyperphosphorylation and subsequent aggregation of the microtubule-associated protein, tau. This event causes the loss of cortical neurons (Duan et al. 2012).

AB is derived by the proteolytic cleavage of the amyloid precursor protein (APP) by the action of three secretases (α-, β-, γ-). There are two kinds of process involving α-secretase, which is the non-amyloidogenic pathway, and beta secretase, in which the toxic peptide AB is produced (Honjo et al. 2012). The processing of alpha e beta secretases is modulated by the protein furin (Seidah et al. 1994) which is involved in modulation of iron homeostasis through the production of soluble hemojuvelin (HJV) (Silvestri et al. 2008), an antagonist of bone morphogenic protein (BMP) mediated activation of hepcidin. Hepcidin is important for iron metabolism (Babbitt et al. 2006). Furin transcription is regulated by cellular iron levels (Silvestri et al. 2008). High levels of this metal decrease furin transcription and impairs the soluble HJV, activating the amyloidogenic pathway. In contrast low levels of iron causes the opposite process, which activates the non amyloidogenic pathway.

The correlation between iron and AD is demonstrated if we consider the control of iron metabolism at the level of mRNAs. There are two iron regulatory proteins, IRP1 and IRP2. In the condition of iron deficiency IRPs bind to stem loops know as iron regulatory elements (IREs) in mRNA. When the IREs are in the 5-untranslated regions (UTR) of mRNA, as in the case of ferritin, ferroportin and amyloid precursor protein (APP) (Cho et al. 2010), binding to IRPs prevents initiation of translation; for DMT1 and transferrin receptor, IREs are in 3’-UTR, binding of the IRPs to IREs protects them against degradation. This results in iron uptake and blockade of iron storage and expression of APP. In the opposite conditions, we have the translations of ferritin, APP and ferroportin with low levels of transferrin and DMT1. In this way iron metabolism and APP expression regulation are strongly connected. As a result, they generate a vicious circle, because the iron excess causes a high production of reactive oxygen species. This ROS could shift to IRP1 to its IRE binding form and increase cellular iron intake via a transferrin receptor.

Aluminum is already involved in neurodegenerative disorders. Bharathi et al. (2008). have demonstrated that exposure to high levels of aluminum leads to NFT and that Al concentration is elevated in degenerating neurons of AD. The Al neurotoxicity is studied in a lot of works. In fact Al stimulates the production of an oligomeric toxic form of amyloid (Drago et al. 2008). By the way Al metabolism is correlated with iron homeostasis: Al stimulates the transcription of H-chain of ferritin with ferrooxidase activity and generates iron dependent oxidative stress, maintaining the chronic flogosis (Campbell et al. 2000).

The correlation between iron and aluminum toxicity is demonstrated by the neuroprotective effects of DFO, the chelating agent used in this case report.
The metal based ROS production in specific brain's regions, based on Fe, Al and Cu levels, can generate the peroxidation of polyunsaturated fatty acids in membrane phospholipids, with the consequent production of reactive aldehydes. In this way it causes damage to proteins with carbonyl functions. The damaged proteins overwhelming the ubiquitin-proteasome system with the generation of intracellular inclusion bodies, which are found in a lot of neurodegenerative diseases (AD, PD, HC etc.) (Lienert & Kozłowski 2012)

CONCLUSIONS

Although a multifactorial pathology like AD can't be addressed by focusing on a single feature, the dysregulation of metals metabolism, not necessarily correlated with serum markers, can represent a promising therapeutic option. In particular, it could be necessary to study the role of other metals, such as copper, and the possibility of a plurichelation of them.

ACKNOWLEDGMENTS

This case report is in the memory of Berardino Di Lorenzo, Physician and Master of Medicine.

REFERENCES


Iron and aluminum in Alzheimer’s disease